Critical Risk-Benefit Assessment of the Novel Anti-Cancer Aurora A Kinase Inhibitor Alisertib (MLN8237): A Comprehensive Review of the Clinical Data

Many current anticancer chemotherapeutics suffer from significant side effects, which have led to the exploration of more targeted therapies. This resulted in the exploration of inhibitors of Aurora A kinase as a potential anti-cancer treatment. Alisertib (MLN8237) has proven to be a potent Aurora A kinase inhibitor that had the highest safety profile among its therapeutic family. Phase I/II/III clinical trials with Alisertib have been carried out and reported promising efficacy, yet serious side effects.
Source: Critical Reviews in Oncology Hematology - Category: Cancer & Oncology Authors: Source Type: research